Freestone Grove Partners’s Phibro Animal Health PAHC Stock Holding History

Freestone Grove Partners’s Portfolio PAHC Stock Details PAHC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$139K	Buy	+4,442	New	+$187K	﹤0.01%	827

Other funds holding PAHC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Freestone Grove Partners's PAHC Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Phibro Animal Health (PAHC) in Q2 2026: 4,442 shares worth $139K. The stake represents ﹤0.01% of the portfolio and ranks #827 among its holdings.

208 funds tracked by Wall St. Rank hold PAHC as of Q2 2026.

Freestone Grove Partners held 4,442 shares of Phibro Animal Health worth $139K as of Q2 2026.
Phibro Animal Health was a new Freestone Grove Partners position in Q2 2026.
Phibro Animal Health made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #827 holding.
208 funds tracked by Wall St. Rank held Phibro Animal Health as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.